The EU Commission conditionally approves a three-part deal in the pharmaceutical sector (Novartis / GSK)

On 28 January 2015, in two separate decisions, the European Commission conditionally approved a complex transaction between pharmaceuticals producers GlaxoSmithKline (GSK) and Novartis that will result in: (i) GSK’s acquisition of Novartis’ human vaccines business; (ii) the formation of a joint venture for consumer healthcare; and (iii) the acquisition by Novartis of GSK’s oncology business. Each element of the transaction involved significant commitments by the parties to address competition concerns.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Porter Elliott, The EU Commission conditionally approves a three-part deal in the pharmaceutical sector (Novartis / GSK), 28 January 2015, e-Competitions January 2015, Art. N° 72122

Visites 443

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues